Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | PRKCI | P41743 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174744 | 0.87 | SMYD3 (0.48) | MAP4K4KDM4EMKNK2AXLPRKCI | |
| SCHEMBL7689552 | 0.85 | TSHR (0.48) | KDM4EMAPKAPK2IP6K1DOT1L | |
| SCHEMBL22113898 | 0.85 | DOT1L (0.41) | KDM4EAXLPRKCIDYRK1BMAPKAPK2 | |
| SCHEMBL15043774 | 0.83 | SLC2A1 (0.53) | KDM4EDYRK1BMAPKAPK2DOT1LSMYD3 | |
| SCHEMBL6202783 | 0.81 | SMYD3 (0.56) | MAP4K4KDM4EMKNK2AXLCSNK2A1 | |
| SCHEMBL27597844 | 0.81 | LCK (0.44) | MAP4K4KDM4EMKNK2AXLCSNK2A1 | |
| SCHEMBL5757121 | 0.81 | MAPKAPK2 (0.45) | MAPKAPK2NR4A2DOT1LCHEK2 | |
| SCHEMBL21620547 | 0.80 | KDM4E (0.47) | MAP4K4KDM4EMKNK2AXLCSNK2A1 | |
| SCHEMBL27159840 | 0.80 | PLK1 (0.56) | AXLDYRK1BCDK8METMERTK | |
| SCHEMBL1299987 | 0.80 | ALOX15 (0.56) | KDM4ECSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4330233-A1 | PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY | Chengdu Anticancer Bioscience, Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| CN-117321036-A | phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity | 成都安泰康赛生物科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| WO-2022228549-A1 | PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY | Chengdu Anticancer Bioscience, Ltd. (CN) | 2022-11-03 | — | — | WO | disclosed |
| WO-2021226458-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| US-6630489-B1 | Quinoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1157008-A1 | QUINOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000050405-A1 | QUINOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | MAP4K4 294/4885KDM4E 4219/4885MKNK2 162/4885 |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | MAP4K4 3561/4885KDM4E 4052/4885MKNK2 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.